Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Lung Neoplasms 2Wilms Tumor 1Sarcoma 1Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Doxorubicin 33Ifosfamide 23Gemcitabine 19pazopanib 18Cyclophosphamide 16Radiotherapy 15pembrolizumab 13Filgrastim 12Docetaxel 12Bevacizumab 10Vincristine 9Sirolimus 9Irinotecan 9Etoposide 9olaratumab 7eribulin 7Sorafenib 7Radiation 7temsirolimus 6Temozolomide 6Mesna 6Magnetic Resonance Spectroscopy 6Cisplatin 6tazemetostat 5cixutumumab 5Trabectedin 5Radiosurgery 5Nivolumab 5Ipilimumab 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma × Glutamic Acid × Clear all
NCT00369564 2021-08-11

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

University of South Florida

Phase 3 Completed
250 enrolled 10 charts
GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡